The new partnership between SCARLETRED and A1-Telekom-Austria enables us the early use of 5G technology and delivers us the opportunity to create a revolutionary new and via AI supported telemedicine for the city of Vienna, its health care professionals and population, which may can go soon far beyond its first target applications in chronic wounds and home care, says CEO Harald Schnidar.
Toggle Navigation
- Research
Back- Research at Vienna BioCenter
- Research Entities
- Research AreasResearch AreasOpen SubmenuBack
- Anthropogenic Evolution
- Biochemistry, Biophysics, Structure
- Cell and Chromosome Biology
- Cognitive and Behavioral Biology
- Computational Biology, Genomes and Evolution
- Disease Mechanisms, Immunology, Pathogens
- Gene Regulation, RNA, Epigenetics
- Microbiology and Environmental Systems Science
- Neurobiology
- Plant Sciences
- Stem Cells, Development, Regeneration
- Research Groups
- Key DiscoveriesKey DiscoveriesOpen Submenu
- Recent Research Highlights
- VBCF
- Companies
Back- Companies at Vienna BioCenter
- Biotech CompaniesBiotech CompaniesOpen SubmenuBack
- a:head
- Ablevia Biotech
- ADvantage Therapeutics
- Affiris CVD GmbH
- aitiologic GmbH
- Akribes
- Austrianni
- BioNTech R&D Austria
- Biosynth
- Bird-C
- bit.bio discovery GmbH
- CALYXHA Biotechnologies
- ChanPharm
- Eveliqure
- Evercyte
- Exscientia
- G.ST Antivirals
- HD Immune
- HeartBeat.bio AG
- HOOKIPA Pharma Inc.
- invIOs
- JLP Health
- Lexogen
- Miti Biosystems
- MyeloPro Diagnostics and Research GmbH
- Myllia Biotechnology
- OncoOne
- Pregenerate
- proxygen GmbH
- QUANTRO Therapeutics
- SCARLETRED
- TAmiRNA
- Thermo Fisher Scientific
- THT Biomaterials GmbH
- Tridem Bioscience
- Valneva
- ViroTrust Diagnostics
- Viverita Discovery
- X4 Pharmaceuticals
- YGION Biomedical GmbH
- Service CompaniesService CompaniesOpen Submenu
- Business IncubatorsBusiness IncubatorsOpen Submenu
- Education
- Career
- About